FDA’s recently enacted budget for this fiscal year included some good news for proponents of nanotechnology  as well as the promise for more in the years ahead. The agency’s National Center for Toxicological Research (NCTR), which conducts research on new medical products like nanomaterials, was approved $60 million for fiscal 2012, flat compared to FY ’11. Sen. Mark Pryor (D-AR) also inserted language in the House-Senate conference report endorsing the development of a nanotechnology core facility. One such site became operational last fiscal year, the other is set for FY 2012. These are among efforts to maintain U.S. leadership in nanotech. Europe is the nearest-term threat, but China, Singapore, and Taiwan are among others. What are your predictions?

Poll Question:
How effective will federal efforts be in maintaining U.S. leadership in nanotech, particularly in the medical field?

A Great Deal


Not Much


Previous articlePoll Voters Believe Geron Will Find a Partner for hESC Therapeutic Programs
Next articleBMS, Simcere to Co-Develop Early-Stage Cardiovascular Disease Candidate